Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
59 participants
INTERVENTIONAL
2012-02-29
2012-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cystic fibrosis (CF) patients
Cystic fibrosis patients whom induced sputum is collected in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliated or benefit from a disease insurance regimen
* Men and women
* Aged from at least 6 years old
* Confirmed Diagnosis of cystic fibrosis based on presence of 2 mutations of CFTR gene and/or 2 positive tests of sweat chloride and/or 2 measures of pathologic difference of nasal potential associated to cystic fibrosis clinical signs.
* Patients able to produce sputum
* Pseudomonas aeruginosa Chronic infected patients
Exclusion Criteria
* Subjet in exclusion period
* Law protected patient
* Realisation of sputum production is contra-indicated
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raphaël RC CHIRON, RC
Role: PRINCIPAL_INVESTIGATOR
CHU de Montpellier - Hôpital Arnaud de Villeneuve
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Montpellier - Hôpital Arnaud de Villeneuve CRCM
Montpellier, Languedoc Roussillon, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UF 8750
Identifier Type: -
Identifier Source: org_study_id